Compare abrdn Income Credit Strategies Fund (ACP) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs BridgeBio Pharma Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while BridgeBio Pharma Inc trades at $77.06 (market cap $15.26B). The key difference: BridgeBio Pharma Inc is far larger — about 23.3× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ACP | BBIO | |
|---|---|---|
Market Cap | $656.21M | $15.26B |
Sector | Financials | Health |
52-Week High | $5.98 | $79.91 |
52-Week Low | $5.01 | $43.19 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $16.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
BridgeBio Pharma (BBIO) trades at $77.91, up 0.93% on the day, supported by a bullish technical outlook and strong analyst consensus. The stock shows robust revenue growth, with 2025 revenue reaching $502.08M, though it remains unprofitable with a net income margin of -124.41%. Recent positive news includes a $1 billion preferred equity raise and regulatory progress for key drug candidates, fueling investor optimism despite ongoing cash burn from operations.
The investment case hinges on the company's pipeline catalysts and commercial execution, with a consensus price target of $102.75 implying significant upside. However, high cash burn, negative equity, and consistent earnings misses present substantial risks, requiring careful monitoring of upcoming clinical and regulatory milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
